Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDB001 + atezolizumab in advanced solid tumors
NCT04196530Phase 1Completed
- Sponsor
- Eikon Therapeutics
- Start
- Nov 2019
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BDB001 in solid tumor (2 arms), sponsored by Eikon Therapeutics. Primary endpoints: Adverse Events at 21 months and Maximum Tolerated Dose at 21 days. Started Nov 2019; status: completed.
02
Drugs
BDB001
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04196530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04196530.